Neurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex.
10.14791/btrt.2016.4.2.111
- Author:
Chang Yong PARK
1
;
Hyun Yong CHOI
;
Sang Ryul LEE
;
Tae Hoon ROH
;
Mi Ra SEO
;
Se Hyuk KIM
Author Information
1. Department of Neurosurgery, Gamma Knife Center, Ajou University School of Medicine, Suwon, Korea. nsksh@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Radiosurgery;
Radiation dosage;
Motor cortex;
Neoplasm metastasis;
Neurologic deficits
- MeSH:
Brain*;
Follow-Up Studies;
Humans;
Life Expectancy;
Motor Cortex*;
Neoplasm Metastasis*;
Neurologic Manifestations;
Prescriptions;
Radiation Dosage;
Radiosurgery*;
Retrospective Studies;
Therapeutic Uses
- From:Brain Tumor Research and Treatment
2016;4(2):111-115
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Although Gamma Knife radiosurgery (GKRS) can provide beneficial therapeutic effects for patients with brain metastases, lesions involving the eloquent areas carry a higher risk of neurologic deterioration after treatment, compared to those located in the non-eloquent areas. We aimed to investigate neurological change of the patients with brain metastases involving the motor cortex (MC) and the relevant factors related to neurological deterioration after GKRS. METHODS: We retrospectively reviewed clinical, radiological and dosimetry data of 51 patients who underwent GKRS for 60 brain metastases involving the MC. Prior to GKRS, motor deficits existed in 26 patients (50.9%). The mean target volume was 3.2 cc (range 0.001–14.1) at the time of GKRS, and the mean prescription dose was 18.6 Gy (range 12–24 Gy). RESULTS: The actuarial median survival time from GKRS was 19.2±5.0 months. The calculated local tumor control rates at 6 and 12 months after GKRS were 89.7% and 77.4%, respectively. During the median clinical follow-up duration of 12.3±2.6 months (range 1–54 months), 18 patients (35.3%) experienced new or worsened neurologic deficits with a median onset time of 2.5±0.5 months (range 0.3–9.7 months) after GKRS. Among various factors, prescription dose (>20 Gy) was a significant factor for the new or worsened neurologic deficits in univariate (p=0.027) and multivariate (p=0.034) analysis. The managements of 18 patients were steroid medication (n=10), boost radiation therapy (n=5), and surgery (n=3), and neurological improvement was achieved in 9 (50.0%). CONCLUSION: In our series, prescription dose (>20 Gy) was significantly related to neurological deterioration after GKRS for brain metastases involving the MC. Therefore, we suggest that careful dose adjustment would be required for lesions involving the MC to avoid neurological deterioration requiring additional treatment in the patients with limited life expectancy.
